Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Common Equity (2016 - 2025)

Protalix BioTherapeutics has reported Common Equity over the past 16 years, most recently at $48.2 million for Q4 2025.

  • Quarterly results put Common Equity at $48.2 million for Q4 2025, up 11.62% from a year ago — trailing twelve months through Dec 2025 was $48.2 million (up 11.62% YoY), and the annual figure for FY2025 was $48.2 million, up 11.62%.
  • Common Equity for Q4 2025 was $48.2 million at Protalix BioTherapeutics, down from $52.9 million in the prior quarter.
  • Over the last five years, Common Equity for PLX hit a ceiling of $52.9 million in Q3 2025 and a floor of -$11.5 million in Q3 2022.
  • Median Common Equity over the past 5 years was $29.2 million (2024), compared with a mean of $20.8 million.
  • Biggest five-year swings in Common Equity: tumbled 5505.63% in 2022 and later skyrocketed 2854.96% in 2024.
  • Protalix BioTherapeutics' Common Equity stood at -$6.0 million in 2021, then plummeted by 76.28% to -$10.6 million in 2022, then skyrocketed by 415.5% to $33.6 million in 2023, then grew by 28.72% to $43.2 million in 2024, then increased by 11.62% to $48.2 million in 2025.
  • The last three reported values for Common Equity were $48.2 million (Q4 2025), $52.9 million (Q3 2025), and $49.9 million (Q2 2025) per Business Quant data.